Caribou Biosciences, Inc. (CRBU) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Caribou Biosciences is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using its proprietary chRDNA genome-editing platform. The company is currently advancing two primary product candidates: vispa-cel (anti-CD19) for B-cell non-Hodgkin lymphoma and CB-011 (anti-BCMA) for multiple myeloma. As of June 30, 2026, the company had an accumulated deficit of $645.9 million and continues to incur operating losses.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Revenue | $1,499 | $2,667 | $3,896 | $5,020 |
| Net Loss | $(24,282) | $(54,098) | $(49,367) | $(94,089) |
| Net Loss Per Share | $(0.24) | $(0.58) | $(0.50) | $(1.01) |
| Operating Expenses | $26,838 | $50,245 | $55,515 | $95,511 |
| Cash & Equivalents | $26,194 | $12,360 | $26,194 | $12,360 |
| Marketable Securities | $87,624 | $130,485 | $87,624 | $130,485 |
| Total Liquidity | $113,818 | $142,845 | $113,818 | $142,845 |
| Cash Used in Operations (6mo) | $(49,771) | $(64,983) | $(49,771) | $(64,983) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 44% year-over-year in Q2 2026 ($1.5M vs $2.7M) and 22% for the six-month period ($3.9M vs $5.0M). This was primarily due to the recognition of a $1.0 million milestone payment in Q2 2025 with no comparable milestone in Q2 2026.
- Significant Expense Reduction: Operating expenses dropped significantly due to strategic pipeline prioritization and workforce reductions announced in April 2025. R&D expenses fell 32% in Q2 2026 ($18.9M vs $27.7M) and 37% for the six-month period ($39.6M vs $63.2M).
- Elimination of One-Time Charges: Q2 2025 included $12.2 million in impairment charges (leasehold improvements, right-of-use assets, lab equipment) and a $9.2 million impairment of an equity investment in Edge Animal Health. These non-recurring charges were absent in Q2 2026, contributing to a narrower net loss.
- Capital Raising: The company raised approximately $20.1 million net of expenses through its At-The-Market (ATM) equity offering program during the six months ended June 30, 2026, compared to no ATM sales in the prior year period.
Outlook, Guidance, and Risks
- Clinical Progress: On May 7, 2026, the company announced alignment with the FDA on the design of ANTLER-3, the planned pivotal Phase 3 trial for vispa-cel. The trial will enroll approximately 250 CD19-naïve second-line large B-cell lymphoma patients. Recent data from the Phase 1 ANTLER trial showed an 82% overall response rate in a specific subgroup.
- Liquidity: Management expects existing cash, cash equivalents, and marketable securities ($113.8 million) to fund operations for at least the next 12 months. However, the company anticipates substantial increases in expenses as it advances clinical trials and may need to raise additional capital in the future.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for continued capital raises, potential delays in regulatory approvals, and the competitive landscape of CAR-T therapies. The company has no approved products and has not generated revenue from product sales.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $113.8 million liquidity position against the projected costs of the ANTLER-3 Phase 3 trial and ongoing operations.
- ATM Program Status: Confirm the remaining capacity under the ATM program ($75.2 million available as of June 30, 2026) and the average share price of recent issuances ($2.03-$2.04).
- Clinical Trial Enrollment: Monitor the initiation and enrollment rates of the ANTLER-3 Phase 3 trial, as delays could impact the timeline for regulatory approval.
- Revenue Concentration: Review the concentration of revenue from top licensees (Party A and Party B accounted for 73% of Q2 2026 revenue) to assess dependency risks.
- Future Milestones: Track potential future milestone payments under license agreements, which totaled approximately $48.9 million as of June 30, 2026.